Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$424M |
| 2 |
Bath & Body Works
BBWI
|
+$342M |
| 3 |
Home Depot
HD
|
+$259M |
| 4 |
GE Aerospace
GE
|
+$247M |
| 5 |
Palo Alto Networks
PANW
|
+$214M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LNKD
LinkedIn Corporation
LNKD
|
+$917M |
| 2 |
ARMH
ARM HOLDINGS PLC ADS
ARMH
|
+$396M |
| 3 |
Citigroup
C
|
+$377M |
| 4 |
Sherwin-Williams
SHW
|
+$292M |
| 5 |
Starbucks
SBUX
|
+$260M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 20.46% |
| 2 | Healthcare | 16.66% |
| 3 | Communication Services | 14.21% |
| 4 | Technology | 13.93% |
| 5 | Financials | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPRS
476
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $7.03M | 0.01% |
2,613,159
+15,291
| +0.6% | +$42.9K |
|
|
HAPN
477
Happen Inc
HAPN
$2.21B
| $6.81M | 0.01% |
164,018
+1,144
| +0.7% | +$48K |
|
478
PUT
Regeneron Pharmaceuticals
REGN
$78.5B
| $6.7M | 0.01% |
+18,600
| New | +$7.66M |
|
479
Corvus Pharmaceuticals
CRVS
$1.12B
| $6.58M | 0.01% |
+464,132
| New | +$6.66M |
|
|
CMRX
480
DELISTED
Chimerix, Inc.
CMRX
| $6.56M | 0.01% |
1,284,070
+10,291
| +0.8% | +$67.2K |
|
|
ACOR
481
DELISTED
Acorda Therapeutics
ACOR
| $6.4M | 0.01% |
2,018
-748
| -27% | -$3.11M |
|
482
Syndax Pharmaceuticals
SNDX
$1.69B
| $5.98M | 0.01% |
+460,892
| New | +$5.79M |
|
|
TRVN
483
DELISTED
Trevena, Inc.
TRVN
| $5.85M | 0.01% |
1,132
+8
| +0.7% | +$40.3K |
|
|
DMTX
484
DELISTED
Dimension Therapeutics, Inc
DMTX
| $5.83M | 0.01% |
745,801
+3,347
| +0.5% | +$26.4K |
|
|
WNRL
485
DELISTED
Western Refining Logistics, LP
WNRL
| $5.75M | 0.01% |
246,071
+40,344
| +20% | +$882K |
|
486
Editas Medicine
EDIT
$396M
| $5.7M | 0.01% |
+170,940
| New | +$4.49M |
|
|
ANAC
487
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $5.34M | 0.01% |
+100,000
| New | +$7.38M |
|
|
LJPC
488
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $5.2M | 0.01% |
+248,574
| New | +$4.43M |
|
489
Wave Life Sciences
WVE
$1.09B
| $5.12M | 0.01% |
370,825
+1,576
| +0.4% | +$22K |
|
490
Oneok
OKE
$57.2B
| $4.96M | 0.01% |
165,980
+29,438
| +22% | +$724K |
|
|
AVXS
491
DELISTED
AveXis, Inc. Common Stock
AVXS
| $4.9M | 0.01% |
+180,001
| New | +$3.93M |
|
|
FCSC
492
DELISTED
Fibrocell Science Inc.
FCSC
| $4.78M | 0.01% |
127,512
-60,290
| -32% | -$2.41M |
|
493
FerroAtlántica
GSM
$594M
| $4.71M | ﹤0.01% |
534,725
+24,954
| +5% | +$215K |
|
|
NS
494
DELISTED
NuStar Energy L.P.
NS
| $4.54M | ﹤0.01% |
112,455
+37,539
| +50% | +$1.31M |
|
|
DSCI
495
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $4.38M | ﹤0.01% |
1,414,487
+6,981
| +0.5% | +$23.4K |
|
496
ExxonMobil
XOM
$644B
| $4.35M | ﹤0.01% |
52,042
-197
| -0.4% | -$15.8K |
|
|
AM
497
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $4.3M | ﹤0.01% |
194,582
+30,271
| +18% | +$645K |
|
|
TVRD
498
Tvardi Therapeutics
TVRD
$19.7M
| $4.11M | ﹤0.01% |
18,353
+118
| +0.6% | +$35.2K |
|
499
USA Compression Partners
USAC
$3.79B
| $4.04M | ﹤0.01% |
343,572
-12,249
| -3% | -$120K |
|
500
Norfolk Southern
NSC
$75.4B
| $3.98M | ﹤0.01% |
47,764
-471,049
| -91% | -$35.6M |
|
Similar funds
Jennison Associates's Q1 2016 Portfolio in Review
As of Q1 2016, Jennison Associates held 710 positions worth $95.3B, down 6.5% from $102B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Jennison Associates's Q1 2016 filing shows 56 new, 303 increased, 241 reduced and 102 closed positions. Its largest new stake was Procter & Gamble: 1,657,581 shares worth $136M. The largest sale was LinkedIn Corporation, an estimated $917M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Communication Services.
- Jennison Associates's largest Q1 2016 buy was Procter & Gamble: 1,657,581 shares worth $136M.
- Jennison Associates added most to Microsoft in Q1 2016, an estimated $424M increase.
- Jennison Associates's biggest Q1 2016 reduction was LinkedIn Corporation, cutting an estimated $917M.
- Jennison Associates fully exited Sherwin-Williams in Q1 2016, selling an estimated $292M.
- Jennison Associates's ten largest holdings make up 24% of its $95.3B portfolio in Q1 2016.
- Jennison Associates opened 56 new positions and closed 102 in Q1 2016.
- Jennison Associates's portfolio value fell 6.5% quarter-over-quarter to $95.3B.
Based on Jennison Associates's 13F filing for Q1 2016, filed 3 May 2016.